Capital International Investors Raises Stock Holdings in Royalty Pharma PLC $RPRX

Capital International Investors boosted its position in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 24.4% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 27,212,694 shares of the biopharmaceutical company’s stock after buying an additional 5,332,074 shares during the quarter. Capital International Investors owned approximately 4.67% of Royalty Pharma worth $960,064,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its position in shares of Royalty Pharma by 868.1% in the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 790 shares during the period. Financial Consulate Inc. bought a new stake in shares of Royalty Pharma in the third quarter worth about $35,000. Richardson Financial Services Inc. purchased a new position in Royalty Pharma during the 3rd quarter valued at about $54,000. Farther Finance Advisors LLC raised its position in Royalty Pharma by 44.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,060 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 632 shares during the last quarter. Finally, Fifth Third Bancorp raised its position in Royalty Pharma by 16.9% during the 3rd quarter. Fifth Third Bancorp now owns 2,499 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 362 shares during the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Terrance P. Coyne sold 34,791 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $46.78, for a total value of $1,627,522.98. Following the sale, the chief financial officer directly owned 45,761 shares of the company’s stock, valued at $2,140,699.58. This represents a 43.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Marshall Urist sold 20,000 shares of the stock in a transaction dated Friday, January 30th. The stock was sold at an average price of $41.09, for a total transaction of $821,800.00. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 737,078 shares of company stock worth $29,862,002. Company insiders own 18.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. The Goldman Sachs Group reiterated a “buy” rating on shares of Royalty Pharma in a research report on Thursday, February 12th. Weiss Ratings upgraded Royalty Pharma from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, February 12th. Wall Street Zen lowered Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. UBS Group raised shares of Royalty Pharma from a “neutral” rating to a “buy” rating and set a $49.00 price objective on the stock in a research report on Friday, January 30th. Finally, TD Cowen restated a “buy” rating on shares of Royalty Pharma in a report on Friday, February 27th. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $48.67.

Royalty Pharma Stock Up 0.3%

RPRX stock opened at $45.97 on Wednesday. Royalty Pharma PLC has a fifty-two week low of $29.66 and a fifty-two week high of $47.86. The company has a market capitalization of $26.52 billion, a price-to-earnings ratio of 34.05 and a beta of 0.40. The business’s 50 day moving average price is $42.81 and its two-hundred day moving average price is $39.37. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.40 and a current ratio of 2.40.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.33 by $0.13. Royalty Pharma had a return on equity of 28.21% and a net margin of 32.38%.The company had revenue of $621.99 million during the quarter, compared to analysts’ expectations of $839.97 million. As a group, analysts forecast that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Shareholders of record on Friday, February 20th were given a dividend of $0.235 per share. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.22. This represents a $0.94 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend was Friday, February 20th. Royalty Pharma’s payout ratio is 69.63%.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.